Radioimmunotherapy for Malignant Mesothelioma Targeting C-ERC/Mesothelin

Our plain-English summary of Radioimmunotherapy for Malignant Mesothelioma Targeting C-ERC/Mesothelin, by H. Hanaoka, A. Yamaguchi, M. Maeda, et al (Pharmaceuticals, 2026).

The study

• Authors: H. Hanaoka, A. Yamaguchi, M. Maeda, T. Segawa, N. Oriuchi
• Journal: Pharmaceuticals
• Published: 2026;19(3)
• Read it: PubMed · Publisher · Free full text

Abstract

Background/Objectives: Malignant mesothelioma has a poor prognosis and limited therapeutic options. C-ERC/mesothelin is highly expressed in mesotheliomas and is a potential target for radioimmunotherapy (RIT). This study evaluated the radiolabeled anti-C-ERC/mesothelin antibody mAb 22A31 as a therapeutic agent. Methods: C-ERC/mesothelin expression in mesothelioma cell lines was assessed by Western blotting, and the specific binding of 125I-labeled mAb 22A31 was examined. Biodistribution of 111In-labeled mAb 22A31 was evaluated in a mesothelioma cell line, MSTO-211H tumor-bearing mice. The therapeutic efficacy of 90Y-labeled mAb 22A31 was evaluated in subcutaneous and pleural dissemination models. Results: mAb 22A31 showed specific binding considering the level of C-ERC/mesothelin expression in each mesothelioma cell line. 111In-mAb 22A31 accumulated in tumors with minimal uptake in normal tissues. 90Y-mAb 22A31 significantly delayed the growth of subcutaneous tumors and improved survival in a pleural dissemination model. Conclusions: Radiolabeled mAb 22A31 specifically targeted C-ERC/mesothelin and demonstrated therapeutic efficacy in a mesothelioma xerograph model. Therefore, 90Y-mAb 22A31 is a promising RIT agent and supports the further development of C-ERC/mesothelin-targeted therapy for mesothelioma.

In plain English

This was a laboratory study in cells and mice. It did not study asbestos exposure or human patients. The authors attached radioactive atoms to an antibody, mAb 22A31, that targets a protein called C-ERC/mesothelin on mesothelioma cells. In three human mesothelioma cell lines, antibody binding rose with each line's level of the protein. In mice with MSTO-211H tumors under the skin, the antibody gathered in the tumors and the liver, with no specific retention in other organs. Yttrium-90-labeled antibody, given into a vein at 3.7 or 5.55 MBq, significantly delayed tumor growth compared with untreated mice, with four mice per group. Some mice had tumor cells injected into the chest, and treatment was given into the chest cavity. Median survival was 51 days with treatment (95% confidence interval 42.8 to 69.6) and 26 days without treatment (22.7 to 46.4), with nine mice per group. The authors concluded the antibody is a promising agent for radioimmunotherapy in mesothelioma. They noted that the cell line used in mice had low levels of the target and that blood and tissue toxicity was not evaluated.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Laboratory (in vitro) and animal experiment testing a radiolabeled antibody as a treatment in mouse models of mesothelioma
• Who was studied: Three human malignant mesothelioma cell lines (MSTO-211H, NCI-H28, NCI-H2052) and BALB/c nude mice carrying MSTO-211H tumors. The distribution study used five mice per time point. The under-the-skin tumor model used four mice per group, and the chest (pleural dissemination) model used nine mice per group. Animal work was approved at Gunma University, Japan.
• Exposure: No asbestos exposure was studied. The 'exposure' was a treatment: the antibody mAb 22A31 labeled with iodine-125 (cell tests), indium-111 (distribution in mice) or yttrium-90 (therapy). In the under-the-skin model, the yttrium-90 antibody was given into a vein at 3.7 MBq or 5.55 MBq. In the pleural model, it was given into the chest cavity at 3.7 MBq.
• Main results:
  • The cell lines made different amounts of the target protein. Relative to NCI-H28, which lacks the protein, the band density was 24.6 for NCI-H2052 and 3.23 for MSTO-211H.
  • In the three cell lines, antibody binding correlated with the amount of target protein (R2 greater than 0.95).
  • In NCI-H2052 cells, the antibody's dissociation constant (Kd) was calculated at 2.67 times 10 to the minus 10 M. The cells carried approximately 90,000 target molecules per cell.
  • In mice with MSTO-211H tumors, the indium-111 antibody accumulated in tumors and in the liver, with no specific retention in other organs. The tumor-to-blood ratio rose over time: 0.08 ± 0.03 at 1 h, 0.61 ± 0.08 at 24 h, and 0.81 ± 0.13 at 48 h.
  • In the under-the-skin model, tumor growth was significantly delayed in both yttrium-90 dose groups compared with untreated controls. The higher dose suppressed growth for longer.
  • One of the four mice given 5.55 MBq lost just under 20% of its body weight and then recovered. No signs of radiation toxicity were seen in the other mice.
  • In the model with tumor cells injected into the chest, treatment was given into the chest cavity. Median survival was 51 days in treated mice (95% confidence interval 42.8 to 69.6) and 26 days in untreated mice (95% confidence interval 22.7 to 46.4). The difference was significant (p less than 0.05).
• The authors' conclusion: The authors concluded that C-ERC/mesothelin is a promising target and that radiolabeled mAb 22A31 is a promising agent for radioimmunotherapy in mesothelioma.
• Limitations the authors state:
  • The mouse experiments used MSTO-211H cells, which have lower levels of the target protein. Ideally, a high-expressing cell line would have been used.
  • Tumor growth could not be monitored in the seeding (chest) model.
  • Because antibody supply was limited, the authors could not run blocking studies in animals or test the antibody alone.
  • Blood (hematological) and tissue (histopathological) toxicity was not evaluated.
  • The number of chelator (DTPA) molecules bound to each antibody was not measured.
  • No therapy experiments with a non-specific control antibody were done, because of restrictions on yttrium-90 use.

Topics

Medical terms in this study, explained in our Lexicon: Mesothelioma, Mesothelin, Prognosis, Mesothelin-Targeted Therapy.

Related studies

• Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect — S. Golfier, C. Kopitz, et al. (2014)
• Inhibition of mesothelin as a novel strategy for targeting cancer cells — K. Wang, V. Bodempudi, et al. (2012)
• Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors — X.Y. Zhao, B. Subramanyam, et al. (2016)
• A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface — Z. Tang, M. Feng, et al. (2013)
• Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors — E. Hatterer, X. Chauchet, et al. (2020)
• Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity — R. Mazor, M. Onda, et al. (2016)

Browse more research in Pharmaceuticals, or return to medical research.